[Pathogenesis of Graves' ophthalmopathy].

Ophthalmopathy, the most frequent extrathyroidal manifestation of Graves' disease, results from an increased volume of the orbital tissues (connective and adipose tissue, interstitial enlargement of extraocular muscles) within the enclosed space of the bony orbits. While the primary antigen is still uncertain, the thyrotropin receptor has recently become a prime candidate because it is expressed both by thyroid epithelial cells and by orbital preadipocyte fibroblasts. Tolerance towards the thyroidal and orbital TSH receptor may be disrupted by bacterial or viral antigens through a "molecular mimicry"-type mechanism. In the context of appropriate costimulatory signals, this would prompt antigen presentation by local dendritic cells and macrophages followed by the recruitment of TSH receptor-specific T cells to the orbital space. As a result, orbital T cells, fibroblasts, adipocytes and perhaps other residential cells would release numerous cytokines, growth factors and inflammatory mediators, many of which act as potent stimulators of glycosaminoglycan accumulation and edema formation. Once initiated, the orbital immune process frequently takes on a momentum of its own, leading to non-specific but nonetheless harmful consequences such as tissue hypoxia, oxygen free radical damage and fibrogenic tissue remodeling. The clinical signs and symptoms of GO reflect the mechanical consequences of increased orbital tissue volume and pressure within the confines of the bony orbits.

[1]  P. Fells,et al.  Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy. , 1989, Clinical and experimental immunology.

[2]  G. Woloschak,et al.  Human retroocular fibroblasts in vitro: a model for the study of Graves' ophthalmopathy. , 1987, The Journal of clinical endocrinology and metabolism.

[3]  C. Gorman,et al.  Diagnosis and Management of Graves' Ophthalmopathy , 1990 .

[4]  N. Bernard,et al.  Prevalence of antibodies reactive with a 64 kDa eye muscle membrane antigen in thyroid-associated ophthalmopathy. , 1991, Thyroid : official journal of the American Thyroid Association.

[5]  J. Sisson Stimulation of glucose utilization and glycosaminoglycans production by fibroblasts derived from retrobulbar tissue. , 1971, Experimental eye research.

[6]  P. Kendall‐Taylor,et al.  OPHTHALMOPATHIC IMMUNOGLOBULIN IN PATIENTS WITH GRAVES' OPHTHALMOPATHY , 1984, The Lancet.

[7]  M. Prummel,et al.  Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. , 1989, The New England journal of medicine.

[8]  A. Weetman Thyroid-associated ophthalmopathy. , 1992, Autoimmunity.

[9]  A. Heufelder,et al.  Graves' immunoglobulins and cytokines stimulate the expression of intercellular adhesion molecule‐1 (ICAM‐1) in cultured Graves' orbital fibroblasts , 1992, European journal of clinical investigation.

[10]  R. Volpe,et al.  Cell-mediated immunity in the exophthalmos of Graves' disease as demonstrated by the migration inhibition factor (MIF) test. , 1973, The Journal of clinical endocrinology and metabolism.

[11]  A. Weetman Autoimmunity in Graves' Ophthalmopathy: A Review , 1989, Journal of the Royal Society of Medicine.

[12]  D. Coleman,et al.  Ultrasonographic evidence of a consistent orbital involvement in Graves's disease. , 1974, The New England journal of medicine.

[13]  J. Wall,et al.  Patients with endocrine ophthalmopathy not associated with overt thyroid disease have multiple thyroid immunological abnormalities. , 1990, The Journal of clinical endocrinology and metabolism.

[14]  J. Mckenzie,et al.  Humoral immunity in Graves' disease. , 1978, Clinics in endocrinology and metabolism.

[15]  S. Lindquist The heat-shock response. , 1986, Annual review of biochemistry.

[16]  C. Gorman,et al.  Detection, cellular localization, and modulation of heat shock proteins in cultured fibroblasts from patients with extrathyroidal manifestations of Graves' disease. , 1991, The Journal of clinical endocrinology and metabolism.

[17]  C. Gorman,et al.  Stimulation of glycosaminoglycan accumulation by interferon gamma in cultured human retroocular fibroblasts. , 1991, The Journal of clinical endocrinology and metabolism.

[18]  A. Taube,et al.  Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. , 1992, The New England journal of medicine.

[19]  C. Rotella,et al.  Ability of monoclonal antibodies to the thyrotropin receptor to increase collagen synthesis in human fibroblasts: an assay which appears to measure exophthalmogenic immunoglobulins in Graves' sera. , 1986, The Journal of clinical endocrinology and metabolism.

[20]  M. Prummel,et al.  Soluble IL‐2 receptor levels in patients with Graves’ophthalmopathy , 1992, Clinical and experimental immunology.

[21]  W. Irvine,et al.  The lack of specificity of ophthalmic immunoglobulins in Graves' disease. , 1986, The Journal of clinical endocrinology and metabolism.

[22]  L. Koornneef Eyelid and orbital fascial attachments and their clinical significance , 1988, Eye.

[23]  J. Rootman,et al.  A 64 kDa membrane antigen is a recurrent epitope for natural autoantibodies in patients with Graves' thyroid and ophthalmic diseases * , 1991, Clinical endocrinology.

[24]  Timothy A. Springer,et al.  Adhesion receptors of the immune system , 1990, Nature.

[25]  P. Yeo,et al.  Ophthalmic Graves's disease: natural history and detailed thyroid function studies. , 1977, British medical journal.

[26]  R. Bahn,et al.  Stimulation of glycosaminoglycan production in cultured human retroocular fibroblasts. , 1992, Investigative ophthalmology & visual science.

[27]  S. Kaufmann,et al.  Heat shock proteins and the immune response. , 1990, Immunology today.

[28]  J. Wall,et al.  Human orbital tissue and thyroid membranes express a 64 kDa protein which is recognized by autoantibodies in the serum of patients with thyroid‐associated ophthalmopathy , 1988, FEBS letters.

[29]  A. Heufelder,et al.  Detection and localization of cytokine immunoreactivity in retro‐ocular connective tissue in Graves' opthalmopathy , 1993, European journal of clinical investigation.

[30]  A. Porcellini,et al.  Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue , 1993, The Lancet.

[31]  G. Vassart,et al.  Cloning and sequencing of a novel 64-kDa autoantigen recognized by patients with autoimmune thyroid disease. , 1991, The Journal of clinical endocrinology and metabolism.

[32]  A. Ahmann,et al.  Antibodies to porcine eye muscle in patients with Graves' ophthalmopathy: identification of serum immunoglobulins directed against unique determinants by immunoblotting and enzyme-linked immunosorbent assay. , 1987, The Journal of clinical endocrinology and metabolism.

[33]  J. Heesemann,et al.  Autoimmune thyroid diseases and enteropathogenic Yersinia enterocolitica. , 1990, Autoimmunity.

[34]  A. Heufelder,et al.  Elevated expression in situ of selectin and immunoglobulin superfamily type adhesion molecules in retroocular connective tissues from patients with Graves’ ophthalmopathy , 1993, Clinical and experimental immunology.

[35]  R. Burde,et al.  Immunohistochemical evidence for C3bi involvement in Graves ophthalmopathy. , 1992, Ophthalmology.

[36]  W. Cobbs,et al.  Immunohistochemical and ultrastructural studies on the exenterated orbital tissues of a patient with Graves' disease. , 1984, Ophthalmology (Rochester, Minn.).

[37]  J. Wall,et al.  Luekocyte adherence inhibition in response to human orbital and lacrimal extracts in patients with Graves’ ophthalmopathy , 1979, Journal of endocrinological investigation.

[38]  D. Weightman,et al.  Cross-reaction of eye muscle antibodies with thyroid tissue in thyroid-associated ophthalmopathy. , 1989, The Journal of endocrinology.

[39]  A. Weetman,et al.  Thyroid-associated eye disease: pathophysiology , 1991, The Lancet.

[40]  C. Gorman,et al.  Increased induction of HLA-DR by interferon-gamma in cultured fibroblasts derived from patients with Graves' ophthalmopathy and pretibial dermopathy. , 1991, The Journal of clinical endocrinology and metabolism.

[41]  A. Sewell,et al.  URINARY GLYCOSAMINOGLYCANS IN Graves'OPHTHALMOPATHY * , 1990, Clinical endocrinology.

[42]  C. Gorman,et al.  Connective tissue, glycosaminoglycans, and diseases of the thyroid. , 1989, Endocrine reviews.

[43]  L. Tallstedt,et al.  Immunohistochemical staining of normal and Graves' extraocular muscle. , 1988, Investigative ophthalmology & visual science.

[44]  C. Gorman,et al.  Presence of antibodies in the sera of patients with Graves' disease recognizing a 23 kilodalton fibroblast protein. , 1989, The Journal of clinical endocrinology and metabolism.

[45]  N. Farid,et al.  GENETIC FACTORS IN GRAVES' OPHTHALMOPATHY , 1986, Clinical endocrinology.

[46]  H. Hansson,et al.  SOMATOMEDIN C IN PATHOGENESIS OF MALIGNANT EXOPHTHALMOS OF ENDOCRINE ORIGIN , 1986, The Lancet.

[47]  C. Gorman,et al.  Hormonal regulation of hyaluronate synthesis in cultured human fibroblasts: evidence for differences between retroocular and dermal fibroblasts. , 1989, The Journal of clinical endocrinology and metabolism.

[48]  C. Dinarello,et al.  The role of interleukin-1 in disease. , 1993, The New England journal of medicine.